Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Obesity Drugs Won't Starve These Other Potential Blockbusters
Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly’s medication were published last week. Source link
Demand for Obesity Drugs Has Insurers Paying Close Attention
Markets Heard on the Street Strong sales of obesity-diabetes drugs known as GLP-1s could affect insurance companies’ financial results Source link
Determined to Flee China, Thousands Take a Long, Dangerous Route to the Southern U.S. Border
In search of economic opportunity or political freedom, Chinese contend with smugglers, bandits and treacherous jungle on the trek through Latin America. Source link
UnitedHealth First-Quarter Earnings, Revenue Up as Company Added Members
Business Earnings Company sees moderate health spending, but higher costs for drugs such as Ozempic Source link
Tonal Founder Steps Down as CEO
The at-home fitness company completed its latest funding round at a fraction of its prior valuation. Source link
Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis
Weight-loss businesses, which long pushed calorie-counting and willpower, are grappling with the surging popularity of new drugs. Source link
Hype Around Weight-Loss Drugs Shows No Signs of Abating. Neither Do the Ads.
Ads for the likes of Ozempic and Wegovy are spreading through social media feeds, subway stations and TV. Source link